Income statement
USD
Annual
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 709M | 817M | 936M |
| Gross Profit | -1M | 0 | 243M | 269M | 266M |
| Operating Income | -1M | -162 | -109M | -53M | -78M |
| EBITDA | -1M | 9 | -85M | -25M | -56M |
| Net Income | 5M | -153 | -52M | -131M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$0.0014
-17.65% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioPlus Acquisition Corp. (BIOSW) is a Financial Services stock with a market cap of $209.07M. The stock last traded around $0.00. Baseline metrics include revenue growth of 0.0%, EPS growth of +138.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +138.7%, free cash flow -81798.5% with operating margin 0.0% and ROIC -0.5%. Valuation already assumes a fairly strong business story at P/E 1249.9. Stock Foundry combines BIOSW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BIOSW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BIOSW Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BIOSW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$935.6M
+14.5% YoY
FY Net Income
-$34.4M
+73.7% YoY
Free Cash Flow
-$52.4M
-455.2% YoY
Revenue Growth
+0.0%
EPS Growth
+138.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 709M | 817M | 936M |
| Gross Profit | -1M | 0 | 243M | 269M | 266M |
| Operating Income | -1M | -162 | -109M | -53M | -78M |
| EBITDA | -1M | 9 | -85M | -25M | -56M |
| Net Income | 5M | -153 | -52M | -131M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Cash & Equivalents | 140K | 636K | 15M | 40M | 10M |
| Total Assets | 238M | 236M | 584M | 603M | 608M |
| Total Liabilities | 15M | 15M | 635M | 606M | 567M |
| Shareholder Equity | 223M | 221M | -51M | -3M | 40M |
| Total Debt | 5M | 5M | 505M | 481M | 452M |
| Net Debt | 5M | 4M | 490M | 441M | 442M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
43M
-5527.6% YoY
Capital Expenditures
10M
-11.1% YoY
Free Cash Flow
52M
-455.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
2.3%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.